Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Cancer and Bone Marrow Transplantation Patients

Protocol
03-123
Full Title
Interindividual Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Oncology/Bone Marrow Transplantation Patients
Purpose

The purpose of this study is to develop tests that will allow doctors to identify genetic differences that may indicate how a patient may respond to cancer chemotherapy and/or the drugs used to prepare for bone marrow transplantation. Patients in this study will include pediatric patients with cancer and patients who will be undergoing a bone marrow transplant.

Investigators will take swabs from the inside of each patient’s cheek as well as blood samples for these genetic tests. These tests will be performed in addition to the usual tests in these patients. Researchers will see if the results of these tests are related to the side effects and effectiveness of the drugs the patients receive. The test results will not alter the course of a patient’s treatment.

Eligibility

Eligible patients include all pediatric cancer patients and those who will undergo bone marrow transplantation at Memorial Sloan-Kettering Cancer Center who have a tumor for which chemotherapy is planned. Patients do not need to be newly diagnosed in order to participate.

For more information and to see if you are or your child is eligible for this study, please Paul Meyers at 212-639-5952.

Disease(s)
Hematology: Hematologic Malignancies
Sarcomas
Locations

Cancer Clinical Trials: Personalizing for Each Patient

Join our experts for a discussion of clinical trials on November 18. Clinical trials can give patients access to new drugs and other treatments before they are widely available, but how do you know if a trial is right for you?

Learn more »